This HTML5 document contains 104 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/AHFS/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00445/identifier/chemspider/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00445/identifier/chebi/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00445/identifier/wikipedia/
n11http://bio2rdf.org/drugbank:
n8http://linked.opendata.cz/resource/drugbank/drug/DB00445/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00445/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB00445/identifier/pubchem-compound/
n23http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00445/identifier/pubchem-substance/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n25http://www.drugs.com/cdi/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00445/identifier/drugbank/
n26http://www.rxlist.com/cgi/generic2/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00445/identifier/national-drug-code-directory/
n13http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00445
rdf:type
n3:Drug
n3:description
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. [PubChem]
n3:dosage
n20:271B5101-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Pharmacia. Ellence® (epirubicin hydrochloride injection) full prescribing information. New York, NY; 2007 Feb.
n3:group
approved
n3:halfLife
Half-lives for the alpha, beta, and gamma phases of about 3 minutes, 2.5 hours and 33 hours, respectively
n3:indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
n3:manufacturer
n4:271B50F2-363D-11E5-9242-09173F13E4C5 n4:271B50F9-363D-11E5-9242-09173F13E4C5 n4:271B50FA-363D-11E5-9242-09173F13E4C5 n4:271B50F7-363D-11E5-9242-09173F13E4C5 n4:271B50F8-363D-11E5-9242-09173F13E4C5 n4:271B50F5-363D-11E5-9242-09173F13E4C5 n4:271B50F6-363D-11E5-9242-09173F13E4C5 n4:271B50F4-363D-11E5-9242-09173F13E4C5 n4:271B50FD-363D-11E5-9242-09173F13E4C5 n4:271B50FB-363D-11E5-9242-09173F13E4C5 n4:271B50F3-363D-11E5-9242-09173F13E4C5 n4:271B50FC-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00445 n23:DB00445
dcterms:title
Epirubicin
adms:identifier
n7:46507282 n8:PA449476 n9:41867 n14:C11230 n15:61703-347-35 n16:DB00445 n17:47898 n18:38201 n19:Epirubicin
n3:mechanismOfAction
Epirubicin has antimitotic and cytotoxic activity. It inhibits nucleic acid (DNA and RNA) and protein synthesis through a number of proposed mechanisms of action: Epirubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. It also interferes with DNA replication and transcription by inhibiting DNA helicase activity.
n3:packager
n4:271B50ED-363D-11E5-9242-09173F13E4C5 n4:271B50EE-363D-11E5-9242-09173F13E4C5 n4:271B50EB-363D-11E5-9242-09173F13E4C5 n4:271B50EC-363D-11E5-9242-09173F13E4C5 n4:271B50F1-363D-11E5-9242-09173F13E4C5 n4:271B50EF-363D-11E5-9242-09173F13E4C5 n4:271B50F0-363D-11E5-9242-09173F13E4C5 n4:271B50E9-363D-11E5-9242-09173F13E4C5 n4:271B50EA-363D-11E5-9242-09173F13E4C5 n4:271B50E7-363D-11E5-9242-09173F13E4C5 n4:271B50E8-363D-11E5-9242-09173F13E4C5 n4:271B50E6-363D-11E5-9242-09173F13E4C5 n4:271B50E4-363D-11E5-9242-09173F13E4C5 n4:271B50E5-363D-11E5-9242-09173F13E4C5 n4:271B50E2-363D-11E5-9242-09173F13E4C5 n4:271B50E3-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Epirubicin and its major metabolites are eliminated through biliary excretion and, to a lesser extent, by urinary excretion.
n3:synonym
Epirubicin Pidorubicinum Epiadriamycin Pidorubicine Epirubicina 4'-Epiadriamycin Epirubicine Pidorubicina Epirubicinum
n3:toxicity
bone marrow aplasia, grade 4 mucositis, and gastrointestinal bleeding
n3:volumeOfDistribution
* 21 ± 2 L/kg [60 mg/m2 Dose] * 27 ± 11 L/kg [75 mg/m2 Dose] * 23 ± 7 L/kg [120 mg/m2 Dose] * 21 ± 7 L/kg [150 mg/m2 Dose]
n12:hasAHFSCode
n22:10-00-00
n3:foodInteraction
Liberal fluid intake to increase urine output and help the excretion of uric acid.
n3:proteinBinding
77%
n3:synthesisReference
Marcel van der Rijst, Johan Wilhelm Scheeren, Dick de Vos, "Process for preparing epirubicin or acid addition salts thereof from daunorubicin." U.S. Patent US5874550, issued September, 1996.
foaf:page
n25:epirubicin.html n26:epirub.htm
n3:IUPAC-Name
n5:271B5106-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B510C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B510B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B5108-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B5109-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B510A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B511C-363D-11E5-9242-09173F13E4C5 n5:271B5104-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B511E-363D-11E5-9242-09173F13E4C5 n5:271B5102-363D-11E5-9242-09173F13E4C5 n5:271B5105-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B5103-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:L01DB03
n3:H-Bond-Acceptor-Count
n5:271B5112-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B5113-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B510D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B510E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B5110-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B510F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B5111-363D-11E5-9242-09173F13E4C5
n3:absorption
100%
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
56420-45-2
n3:category
n3:clearance
* 65 +/- 8 L/hour [Patients1 with Solid Tumors Receiving Intravenous Epirubicin 60 mg/m2] * 83 +/- 14 L/hour [Patients1 with Solid Tumors Receiving Intravenous Epirubicin 75 mg/m2] * 65 +/- 13 L/hour [Patients1 with Solid Tumors Receiving Intravenous Epirubicin 120 mg/m2] * 69 +/- 13 L/hour [Patients1 with Solid Tumors Receiving Intravenous Epirubicin 150 mg/m2]
n3:containedIn
n21:271B50FE-363D-11E5-9242-09173F13E4C5 n21:271B50FF-363D-11E5-9242-09173F13E4C5 n21:271B5100-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B5118-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B511A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B511B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B511D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B5117-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B5116-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B5119-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B5107-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B5114-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B5115-363D-11E5-9242-09173F13E4C5